CLYM
Climb Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$10.92
+12.26%Price chart
Sep 21Sep 24Sep 29Oct 2Oct 7Oct 12Oct 15Oct 20
Key dataOct 20, 2026
Open$9.84
From 52W high−38.78%
Volume595253.00
Market cap$627.35M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 20, 2026
Open
$9.84
From 52W high
−38.78%
Volume
595253.00
Market cap
$627.35M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−7.5x
P/E (TTM)
—
RSI (14)
41.3
MomentumView details →
1D Return
+12.26%
YTD Return
+166.62%
SummaryUpdated Jun 1, 2026
Climb Bio, Inc. (NASDAQ:CLYM) is a clinical-stage biotechnology company founded in 2018 and headquartered in Wilmington, Delaware. The company was originally incorporated as Eliem Therapeutics, Inc. before changing its name to Climb Bio in October 2024. Climb Bio focuses on developing innovative therapies for autoimmune-driven inflammatory diseases, with its lead drug candidate budoprutug currently in clinical development for multiple autoimmune conditions including systemic lupus erythematosus and lupus nephritis.
Similar companies
Latest newsMore news →
Climb Bio announced it will present new data on CLYM116 and budoprutug at the American Society of Nephrology (ASN) Kidney Week 2026, including preliminary Phase 2 data from the ongoing PrisMN study of budoprutug in primary membranous nephropathy selected for oral presentation.18d agoClimb Bio Inc. released preliminary data from its ongoing Phase 1 trial of CLYM116 for IgA nephropathy and announced updated strategic plans for the treatment.47d agoClimb Bio, Inc. reported a net loss of $13.5 million for Q2 2026, compared to a net loss of $8.7 million in Q2 2025.76d ago